Want to join the conversation?
$PFE's 3Q15 reported revenues reflects YoverY operational growth of 6% mainly driven by the strong performance in developed markets from Prevnar 13 adult, Ibrance and Eliquis as well as from Lyrica primarily in the U.S., one month of legacy Hospira in US and 5% operational growth in emerging markets mainly from Innovative Products.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.